Intermune (ITMN) 10-Q 1 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 25, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'ITMN	'
Entity Registrant Name	'INTERMUNE INC	'
Entity Central Index Key	'0001087432	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	82,028,195

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$117,285	$117,748
Available-for-sale securities	219,959	190,238
Accounts receivable, net	16,554	6,767
Inventories	10,423	10,020
Prepaid expenses and other current assets	9,384	6,878
Total current assets	373,605	331,651
Property and equipment, net	4,618	4,332
Acquired product rights, net	17,500	18,250
Other assets (includes restricted cash of $4,807 at September 30, 2013 and $3,813 at December 31, 2012)	12,183	9,233
Total assets	407,906	363,466
Current liabilities:	'	'
Accounts payable	8,476	18,887
Accrued compensation	13,479	11,528
Other accrued liabilities	27,051	26,256
Total current liabilities	49,006	56,671
Convertible notes	263,611	240,250
Other long-term liabilities	221	228
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value; 5,000 shares authorized, no shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	'	'
Common stock, $0.001 par value; 175,000 and 100,000 shares authorized; 81,973 and 66,050 shares issued and outstanding at September 30, 2013 and December 31, 2012	82	66
Additional paid-in capital	1,354,905	1,163,700
Accumulated other comprehensive income	698	501
Accumulated deficit	-1,260,617	-1,097,950
Total stockholders' equity	95,068	66,317
Total liabilities and stockholders' equity	$407,906	$363,466

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Other assets, restricted cash	$4,807	$3,813
Preferred stock, par value	$0.00	$0.00
Preferred stock, Shares authorized	5,000	5,000
Preferred stock, Shares issued	'	'
Preferred stock, Shares Outstanding	'	'
Common stock, par value	$0.00	$0.00
Common stock, Shares authorized	175,000	100,000
Common stock, Shares issued	81,973	66,050
Common stock, Shares Outstanding	81,973	66,050

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue, net	'	'	'	'
Sales revenue, net	$19,718	$7,534	$44,648	$17,952
Cost and expenses:	'	'	'	'
Cost of goods sold	2,759	2,017	7,078	6,200
Research and development	27,316	26,175	80,723	74,553
Selling, general and administrative	35,219	23,754	102,468	75,680
Total costs and expenses	65,294	51,946	190,269	156,433
Loss from operations	-45,576	-44,412	-145,621	-138,481
Other income (expense):	'	'	'	'
Interest income	93	148	345	452
Interest expense	-3,667	-2,031	-10,784	-6,473
Change in value of embedded conversion derivative	'	'	2,422	'
Loss on extinguishment of debt	'	'	-7,900	'
Other	-851	975	-945	-149
Loss from continuing operations before income taxes	-50,001	-45,320	-162,483	-144,651
Income tax expense (benefit)	241	-4,319	1,121	-13,708
Loss from continuing operations, net of taxes	-50,242	-41,001	-163,604	-130,943
Income from discontinued operations, net of taxes	320	84	937	34,139
Net loss	($49,922)	($40,917)	($162,667)	($96,804)
Basic and diluted net loss per common share:	'	'	'	'
Continuing operations	($0.62)	($0.63)	($2.04)	($2.02)
Discontinued operations	$0.01	'	$0.01	$0.53
Net loss	($0.61)	($0.63)	($2.03)	($1.49)
Shares used in computing basic and diluted net loss per common share	81,397	65,183	80,021	64,966

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net loss	($49,922)	($40,917)	($162,667)	($96,804)
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation adjustment	845	-755	181	-536
Unrealized gains (losses) on available-for-sale securities:	'	'	'	'
Unrealized gains (losses) during period	149	104	14	81
Less: Reclassification adjustments for gains transferred to net loss	'	'	2	'
Total other comprehensive income (loss)	994	-651	197	-455
Comprehensive loss	($48,928)	($41,568)	($162,470)	($97,259)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows used in operating activities:	'	'
Net loss	($162,667)	($96,804)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Stock-based compensation expense	8,964	12,254
Amortization of debt discount and debt issuance costs	5,016	611
Change in fair value of embedded conversion derivative	-2,422	'
Gain on sale of discontinued operations	'	-51,335
Depreciation and amortization expense	2,027	1,567
Loss on extinguishment of debt	7,900	'
Net realized gains on sales of available-for-sale securities	-2	'
Other	174	-443
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	-9,787	-1,388
Inventories	-403	-4,643
Prepaid expenses	-2,506	'
Other assets	-236	1,557
Accounts payable and accrued compensation	-8,460	1,765
Other accrued liabilities	795	8,526
Net cash used in operating activities	-161,607	-128,333
Cash flows from investing activities:	'	'
Proceeds from the divestiture of Actimmune	'	55,000
Purchases of property and equipment	-1,563	-2,510
Purchases of available-for-sale securities	-191,607	-265,281
Maturities of available-for-sale securities	140,890	186,201
Sales of available-for-sale securities	21,014	40,043
Net cash (used in) provided by investing activities	-31,266	13,453
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock in a public offering, net of issuance costs	145,734	'
Proceeds from convertible senior notes, net of issuance costs	116,800	'
Repurchase of convertible senior notes	-72,183	'
Proceeds from issuance of common stock under employee stock benefit plans	2,059	2,055
Net cash provided by financing activities	192,410	2,055
Net decrease in cash and cash equivalents	-463	-112,825
Cash and cash equivalents at beginning of period	117,748	234,928
Cash and cash equivalents at end of period	117,285	122,103
Supplemental disclosure of cash flow information:	'	'
Interest paid in cash	7,305	8,088
Non-cash financing activities:	'	'
Reclassification of derivative liability to stockholders' equity	$34,465	'

Organization

Organization	9 Months Ended
	Sep. 30, 2013
Organization	'
	1. ORGANIZATION
	Overview
	We are a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. We have a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. Pirfenidone was granted marketing authorization effective February 2011 in all 28 member countries of the European Union, or the EU, for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis, or IPF. In September 2011, we launched commercial sales of pirfenidone in Germany under the trade name Esbriet, and Esbriet is now also commercially available in Austria, Belgium, Denmark, Finland, France, Iceland, Ireland, Luxembourg, Norway and Sweden. In January 2013, Esbriet became commercially available in Canada. During the quarter, we obtained approval for reimbursement of Esbriet from the Scottish Medicines Consortium (SMC) and Ireland’s Health Service Executive (HSE), and we launched Esbriet in Italy in July 2013 and in the UK in August 2013.
	We are also pursuing the registration of pirfenidone to treat IPF in the United States. After reviewing various regulatory and clinical development options and following our discussions with the United States Food and Drug Administration (“FDA”), we commenced an additional pivotal Phase 3 clinical study of pirfenidone in IPF in July 2011, known as the ASCEND trial. The results of the ASCEND trial are expected to supplement the existing Phase 3 clinical study data from our CAPACITY clinical trials to support the registration of pirfenidone to treat IPF in the United States. We completed enrollment with 555 randomized patients for our ASCEND trial in January 2013.
	This quarter, we initiated a randomized, double-blind, placebo controlled Phase 2 clinical study, known as the PANORAMA trial, designed to evaluate the safety and tolerability of N–Acetylcysteine (NAC) in patients with IPF and who are being treated with Esbriet® (pirfenidone). We also initiated our LOTUSS trial which will be a Phase 2, multinational, open-label, randomized, parallel-group, safety and tolerability study of Esbriet (pirfenidone) in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
	On June 19, 2012, we completed the divestiture of our worldwide development and commercialization rights to the pharmaceutical product containing Interferon Gamma-1b sold by us under the trade name Actimmune for $55.0 million in cash, plus certain conditional royalty payments for a period of two years following the closing. Such divestiture was consummated pursuant to the terms of the Asset Purchase Agreement, dated as of May 17, 2012, that we entered into with Vidara Therapeutics International Limited, an Irish company, Vidara Therapeutics Holdings LLC, a Delaware limited liability company and Vidara Therapeutics Research Limited, an Irish company. The operating results of our Actimmune activities have been reclassified as discontinued operations for all periods presented. As a consequence of the divestiture, we were required to apply intraperiod tax allocation rules for the purposes of calculating our provision for income taxes.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies	'
	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Our significant accounting policies and recent accounting pronouncements were described in Note 2 to our Consolidated Financial Statements included in our 2012 Annual Report on Form 10-K for the fiscal year ended December 31, 2012. There have been no significant changes in our accounting policies since December 31, 2012.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. The financial statements include all adjustments (consisting only of normal recurring adjustments) that we believe are necessary for a fair presentation of the periods presented. The condensed consolidated balance sheet at December 31, 2012 was derived from the audited consolidated financial statements, but does not include all disclosures required by GAAP. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year or any other future period and should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2012, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC).
	Revenue Recognition and Revenue Reserves
	Revenue is generated from product sales and recorded net of rebates. We only ship product upon receipt of valid orders from customers, such as pharmacies and hospitals, which are in turn a result of actual patient prescriptions. Delivery is considered to have occurred when title passes to a credit-worthy customer. We include shipping and handling costs in cost of goods sold. Pursuant to terms and conditions of sale, our customers have no rights to return our products. Such restriction on product returns is common practice in the markets in which we sell, and as a result, we have had no significant expenses related to product returns, damaged or expired goods, chargebacks, except for mandatory government rebates, or other discounts or allowances since our commercial launch in these countries. Product sales are recorded net of estimated government-mandated rebates which are fixed for negotiated periods. We review all sales transactions for potential rebates each month and believe that our reserves are adequate. Due to our limited history of selling Esbriet, we are currently accruing for these mandatory government rebates according to contractual obligation redemption rates, which represents our best estimate of the liability at this time and as we develop a more substantial history related to our rebate claims, we will continue to adjust our accrual to accurately reflect rebate claims.
	Derivative Financial Instruments
	On January 22, 2013, we issued $120.8 million aggregate principal amount of 2.50% convertible senior notes due 2017 (the “2017 Notes”). As a result of our issuance of the 2017 Notes, our total potential outstanding common stock exceeded our authorized shares by approximately 4.3 million shares as of that date and we were therefore required to value the embedded conversion derivative and recognize it at fair value as a long-term liability.
	On May 30, 2013, we obtained stockholder approval to an amendment to our certificate of incorporation to increase the number of our authorized shares of common stock from 100,000,000 to 175,000,000. As a result of the increase in authorized number of shares, we can now settle the 2017 Notes in cash, stock, or a combination thereof, solely at our election, the derivative associated with the embedded conversion derivative was marked to fair value at May 30, 2013 and the long-term liability was reclassified to stockholders’ equity.
	See also Note 10 for further details of our embedded conversion derivative.
	Royalty Payments
	We record royalty payments due on product sales within cost of goods sold. At present, the only such royalty is payable to Shionogi in relation to net sales of pirfenidone in the EU.
	Net Loss Per Share
	Basic net loss per share is calculated based on the weighted-average number of shares of our common stock outstanding during the period, as adjusted. Diluted net loss per share is calculated based on the weighted average number of shares of our common and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and shares subject to repurchase are determined under the treasury stock method. The potential dilutive shares of our common stock issuable on conversion of our convertible notes are determined using the “if-converted” method.
	For the calculation of net loss per share, securities excluded were as follows:
		As of
		September 30,
		2013			2012
		(in thousands)
	Common stock options and awards		5,797			5,252
	Shares issuable upon conversion of convertible notes		15,237			9,384
	The following table is a reconciliation of the denominator used in the calculation of basic and diluted net loss per share attributable to our common stockholders:
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013			2012
		(in thousands)
	Denominator:
	Weighted-average shares of common stock outstanding		81,942			65,779			80,604			65,497
	Less: Weighted-average shares subject to repurchase		(545	)		(596	)		(583	)		(531	)
	Weighted-average shares used in computing net loss per common share – basic and diluted		81,397			65,183			80,021			64,966
	Stock-Based Compensation
	The following table reflects stock-based compensation expense recognized for the three and nine month periods ended September 30, 2013 and 2012:
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013			2012
		(in thousands)
	Cost of goods sold	$	(4	)	$	50		$	39		$	157
	Research and development		1,044			1,070			2,708			3,510
	Selling, general and administrative		2,431			2,031			6,217			8,587
	Total stock-based compensation expense	$	3,471		$	3,151		$	8,964		$	12,254
	Under the fair value recognition provisions of Accounting Standards Codification (ASC) 718-10, Stock Compensation, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period for that portion of the award that is ultimately expected to vest. In order to estimate the value of share-based awards, we use the Black-Scholes model, which requires the use of certain subjective assumptions. The most significant assumptions are our estimates of the expected volatility, the expected term of the award and the estimated forfeiture rate.
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. This ASU is an update to the reporting of reclassifications out of accumulated other comprehensive income. The guidance requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety from accumulated other comprehensive income to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. The guidance is effective for us in our first quarter of fiscal year 2014 with earlier adoption permitted, which should be applied prospectively. We adopted ASU No. 2013-02 for the period ended March 31, 2013. The adoption of this new guidance did not have an effect on our condensed consolidated balance sheets, statement of operations or cash flows.

Discontinued_Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2013
Discontinued Operations	'
	3. DISCONTINUED OPERATIONS
	On June 19, 2012, we completed the divestiture of our worldwide development and commercialization rights to the pharmaceutical product containing Interferon Gamma-1b sold by us under the trade name Actimmune for $55.0 million in cash, plus certain conditional royalty payments for a period of two years following the closing (the transaction is referred to herein as the “Asset Sale”). The Asset Sale was consummated pursuant to the terms of the Asset Purchase Agreement, dated as of May 17, 2012, by and among InterMune and Vidara Therapeutics International Limited, an Irish company, Vidara Therapeutics Holdings LLC, a Delaware limited liability company and Vidara Therapeutics Research Limited, an Irish company, as amended on June 18, 2012. The operating results of our Actimmune activities have been reclassified as discontinued operations for all periods presented. As a consequence of the divestiture, we were required to apply intraperiod tax allocation rules for the purposes of calculating our provision for income taxes.
	Results of Discontinued Operations
	Summary operating results for the discontinued operations are as follows:
		Three Months					Nine Months
		Ended September 30,					Ended September 30,
		2013		2012			2013		2012
		(in thousands)
	Actimmune revenue, net	$	500	$	—		$	1,500	$	6,627
	Costs and expenses:
	Cost of goods sold		—		(198	)		—		4,276
	General and administrative		15		66			80		226
	Total costs and expenses		15		(132	)		80		4,502
	Income from discontinued operations		485		132			1,420		2,125
	Gain on sale of discontinued operations		—		—			—		51,335
	Income and gains related to discontinued operations, before tax		485		132			1,420		53,460
	Income tax expense		165		48			483		19,321
	Income from discontinued operations, net of taxes	$	320	$	84		$	937	$	34,139

Derivative_Instruments

Derivative Instruments	9 Months Ended
	Sep. 30, 2013
Derivative Instruments	'
	4. DERIVATIVE INSTRUMENTS
	In connection with our continuing expansion efforts, we now conduct business throughout Europe in several currencies, including the euro, Swiss franc and British pound, among others. Therefore, we are exposed to adverse movements in foreign currency exchange rates. To limit the exposure related to foreign currency changes, we enter into foreign currency contracts. We do not enter into such contracts for trading or speculative purposes.
	We enter into foreign exchange forward contracts to reduce the short-term effects of foreign currency fluctuations on assets and liabilities such as foreign currency receivables and payables. These derivatives are not designated as hedging instruments. Gains and losses on the contracts are included in other income (expense) and substantially offset foreign exchange gains and losses from the remeasurement of intercompany balances or other current assets or liabilities denominated in currencies other than the functional currency of the reporting entity. Our net losses from entering into derivative financial instruments not designated as hedges for the three month period ended September 30, 2013 was $0.5 million compared to net losses of $0.2 million in the same period in 2012. Our net losses for the nine month periods ended September 30, 2013 was $0.4 million compared to net gains of $0 in the same period in 2012. The notional value of our outstanding currency hedges at September 30, 2013 and December 31, 2012 was 9.5 million euros and 6.0 million euros, respectively, and the fair value of these outstanding derivatives at September 30, 2013 and December 31, 2012 were zero.
	Our foreign exchange forward contracts expose us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting counterparties to major financial institutions. In addition, the potential risk of loss with any one counterparty resulting from this type of credit risk is monitored. We do not generally require collateral to be pledged under these agreements. We do not expect material losses as a result of defaults by counterparties.
	In addition to our foreign exchange forward contract derivative instruments, we also had an embedded derivative option related to our 2017 Notes. See Note 10 to these financial statements for details of our embedded conversion derivative.

Fair_Value

Fair Value	9 Months Ended
	Sep. 30, 2013
Fair Value	'
	5. FAIR VALUE
	In accordance with ASC 820-10, Fair Value Measurements and Disclosures, we determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:
		•		Level 1 inputs which include quoted prices in active markets for identical assets or liabilities;
		•		Level 2 inputs which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our available-for-sale securities, we review trading activity and pricing as of the measurement date. For our convertible senior notes we determined the fair value based on quoted market values. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and
		•		Level 3 inputs which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.
	The following table represents the fair value hierarchy for our financial assets which require fair value measurement on a recurring basis as of September 30, 2013 and December 31, 2012:
			As of September 30, 2013
			(in thousands)
	Assets		Level 1		Level 2		Level 3			Total
	Money market funds		$	24,532	$	—	$	—		$	24,532
	Obligations of government-sponsored enterprises			—		181,489		—			181,489
	Corporate debt securities			—		27,975		—			27,975
	Commercial paper			—		10,495		—			10,495
	Total		$	24,532	$	219,959	$	—		$	244,491
			As of December 31, 2012
			(in thousands)
	Assets		Level 1		Level 2		Level 3			Total
	Money market funds		$	7,777	$	—	$	—		$	7,777
	Obligations of government-sponsored enterprises			—		144,806		—			144,806
	Corporate debt securities			—		31,438		—			31,438
	Commercial paper			—		32,891		—			32,891
	Total		$	7,777	$	209,135	$	—		$	216,912
	The following table summarizes the carrying and fair value of our Level 2 convertible senior notes as of September 30, 2013 and December 31, 2012:
			As of September 30, 2013				As of December 31, 2012
			(in thousands)
			Carrying value		Fair value		Carrying value			Fair value
	Convertible senior notes due 2015		$	18,360	$	21,514	$	85,000		$	85,286
	Convertible senior notes due 2017			90,001		170,102		—			—
	Convertible senior notes due 2018			155,250		140,389		155,250			121,326
	Total		$	263,611	$	332,005	$	240,250		$	206,612
	Embedded Conversion Derivative
	The embedded conversion derivative on the 2017 Notes was reclassified to stockholders’ equity on May 30, 2013 in connection with the approval of an amendment to our certificate of incorporation increasing our authorized number of shares of common stock. The embedded conversion derivative was classified as Level 3 because this liability was not actively traded and was valued using a binomial lattice model. Significant inputs to this model were the remaining time to maturity, volatility and risk-free interest rate.
	The following table sets forth the changes in the estimated fair value for our Level 3 classified embedded conversion derivative:
			Three Months				Nine Months
			Ended September 30,				Ended September 30,
			2013		2012		2013			2012
			(in thousands)
	Fair value measurement at beginning of period		$	—	$	—	$	—		$	—
	Embedded conversion derivative recorded in connection with 2017 Notes			—		—		36,887			—
	Change in fair value measurement included in operating expenses			—		—		(2,422	)		—
	Derivative liability reclassified to stockholders’ equity			—				(34,465	)
	Fair value measurement at end of period		$	—	$	—	$	—		$	—

Cash_Equivalents_and_Available

Cash Equivalents and Available-For-Sale Securities	9 Months Ended
	Sep. 30, 2013
Cash Equivalents and Available-For-Sale Securities	'
	6. CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES
	The following table is a summary of available-for-sale debt and equity securities included in cash and cash equivalents or available-for-sale securities:
	September 30, 2013	Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(in thousands)
	Money market funds	$	24,532	$	—	$	—	$	24,532
	Obligations of government-sponsored enterprises		181,375		114		—		181,489
	Corporate debt securities		27,957		18		—		27,975
	Commercial paper		10,495		—		—		10,495
	Total	$	244,359	$	132	$	—	$	244,491
		Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(in thousands)
	Reported as:
	Cash equivalents	$	24,532	$	—	$	—	$	24,532
	Available-for-sale securities		219,827		132		—		219,959
	Total	$	244,359	$	132	$	—	$	244,491
	December 31, 2012	Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(in thousands)
	Money market funds	$	7,777	$	—	$	—	$	7,777
	Obligations of government-sponsored enterprises		144,747		59		—		144,806
	Corporate debt securities		31,382		56		—		31,438
	Commercial paper		32,890		1		—		32,891
	Total	$	216,796	$	116	$	—	$	216,912
		Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(in thousands)
	Reported as:
	Cash equivalents	$	26,674	$	—	$	—	$	26,674
	Available-for-sale securities		190,122		116		—		190,238
	Total	$	216,796	$	116	$	—	$	216,912
	Realized gains and losses calculated based on the specific identification method were $0 and $2,000 for the three and nine months ended September 30, 2013, respectively, and $0 for the three and nine months ended September 30, 2012.
	The following is a summary of the amortized cost and estimated fair value of available-for-sale securities by contractual maturity:
		September 30, 2013
		Amortized		Fair Value
		Cost
		(in thousands)
	Mature in less than one year	$	189,027	$	189,112
	Mature in one to three years		55,332		55,379
	Total	$	244,359	$	244,491

Inventory

Inventory	9 Months Ended
	Sep. 30, 2013
Inventory	'
	7. INVENTORIES
	Inventories consist of the following:
		September 30,		December 31,
		2013		2012
		(in thousands)
	Raw materials	$	7,878	$	7,310
	Work in process		1,461		1,097
	Finished goods		1,084		1,613
	Total	$	10,423	$	10,020

Comprehensive_Loss

Comprehensive Loss	9 Months Ended
	Sep. 30, 2013
Comprehensive Loss	'
	8. COMPREHENSIVE LOSS
	The balance of accumulated other comprehensive income (loss), net of taxes, was as follows:
		Foreign		Unrealized gains		Accumulated
		Currency		(losses) on		other
				securities		comprehensive
						income
		(in thousands)
	Balance at December 31, 2012	$	385	$	116	$	501
	Comprehensive loss		181		16		197
	Balance at September 30, 2013	$	566	$	132	$	698
	Realized gains and losses of $0 and $2,000 were reclassified to other income (expense) on the statement of operations for the three and nine months ended September 30, 2013, respectively, and $0 for the three and nine months ended September 30, 2012.

Convertible_Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2013
Convertible Notes	'
	9. CONVERTIBLE NOTES
	In June 2008, we issued $85.0 million in 5.00% convertible senior notes due 2015 (the “2015 Notes”). The 2015 Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of our existing senior debt, and rank senior in right of payment to all of our existing subordinated debt. Interest accrues from the date of issuance and is payable in arrears on March 31 and September 30 of each year commencing on September 30, 2008. The 2015 Notes will mature on March 1, 2015. Holders of the 2015 Notes may surrender their notes, in integral multiples of $1,000 principal amount, for conversion any time prior to the close of business on the second business day immediately preceding the maturity date. The initial conversion rate for each $1,000 aggregate principal amount of the 2015 Notes is 52.9661 shares of common stock, equivalent to a conversion price of approximately $18.88 per share. Offering expenses and underwriting discounts in the aggregate of approximately $0.6 million related to the sale of the 2015 Notes were recorded in other assets and are being amortized to interest expense using the effective interest method over the term of the 2015 Notes, which is approximately seven years from the date of issuance. At September 30, 2013, $18.4 million of principal remained outstanding under the 2015 Notes.
	In September 2011, we issued $155.3 million in 2.50% convertible senior notes due 2018 (the “2018 Notes”). The 2018 Notes are general unsecured senior obligations of the Company and rank equal in right of payment with the Company’s other senior unsecured debt and rank senior in right of payment to all of our existing and future subordinated debt. Interest accrues from the date of issuance and is payable in arrears on September 15 and March 15 of each year commencing on March 15, 2012. The 2018 Notes will mature on September 15, 2018. Holders of the 2018 Notes may surrender their notes, in integral multiples of $1,000 principal amount, for conversion any time prior to the close of business on the second business day immediately preceding the maturity date. The initial conversion rate for each $1,000 aggregate principal amount of the 2018 Notes is 31.4465 shares of common stock, equivalent to a conversion price of approximately $31.80 per share. Offering expenses and underwriting discounts in the aggregate of approximately $5.0 million related to the sale of the 2018 Notes were recorded in other assets and are being amortized to interest expense using the effective interest method over the term of the 2018 Notes, which is approximately seven years from the date of issuance. At September 30, 2013, $155.3 million of principal remained outstanding under the 2018 Notes.
	The following is a summary of the interest expense recognized on the 2015 and 2018 Notes:
		Three Months				Nine Months
		Ended September 30,				Ended September 30,
		2013		2012		2013		2012
		(in thousands)
	Convertible senior notes due 2015	$	235	$	1,087	$	907	$	3,260
	Convertible senior notes due 2018		1,150		1,150		3,450		3,450
	Total interest expense	$	1,385	$	2,237	$	4,357	$	6,710
	In January 2013, we completed a registered underwritten public offering of 15,525,000 shares of our common stock (“Common Stock Offering”) and a concurrent registered underwritten public offering of $120.8 million aggregate principal amount of 2.50% convertible senior notes due December 15, 2017 (the “2017 Notes” and the “Convertible Note Offering”). The resulting aggregate net proceeds from the Common Stock Offering were approximately $145.7 million, after deducting underwriting discounts and estimated expenses. The resulting aggregate net proceeds from the Convertible Note Offering were approximately $116.8 million, after deducting underwriting discounts and estimated expenses. Interest accrues from the date of issuance and is payable in arrears on June 15 and December 15 of each year commencing on June 15, 2013. The holders of the 2017 Notes may convert their 2017 Notes into shares of our common stock at a conversion rate of 77.7001 shares per $1,000 principal amount of notes, subject to adjustment (representing a conversion price of approximately $12.87 per share). We can settle conversion of the 2017 Notes by delivery of shares, cash or a combination of shares and cash at our election.
	Conversion of the 2017 Notes may occur on any day prior to September 15, 2017, under the following conditions: a) during any fiscal quarter beginning after June 30, 2013, if the last reported sale price of our common stock for at least 20 trading days during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; b) during the five consecutive business day period after any five consecutive trading day period in which the trading price of the 2017 Notes falls below 98% of the product of (i) the last reported sale price of the Company’s common stock and (ii) the applicable conversion rate on each such trading date; c) if we call the 2017 Notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; and d) upon the occurrence of specified corporate events, as defined in the 2017 Notes. From September 15, 2017 until the close of business on the second scheduled trading day immediately preceding the December 15, 2017 maturity date, holders of the 2017 Notes may convert their notes at any time, regardless of the foregoing circumstances.
	On or after June 20, 2015, we may redeem for cash all or part of the 2017 Notes (except for Notes that holders have already required us to repurchase following certain fundamental changes defined within the agreement such as an acquisition or liquidation of the Company) but only if the last reported sale price of our common stock for 20 or more trading days in a period of 30 consecutive trading days ending within 10 trading days of immediately prior to the date we provide the notice of redemption exceeds 130% of the conversion price in effect on each such trading day. The redemption price in this case will equal 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
	Other than restrictions relating to certain fundamental changes and consolidations, mergers or asset sales and customary anti-dilution adjustments, the 2017 Notes do not contain any financial covenants and do not restrict us from paying dividends or issuing new securities or repurchasing any of our other securities.
	In January 2013, we used a portion of the net proceeds from the Convertible Note Offering to repurchase approximately $66.6 million of our outstanding 2015 Notes for proceeds of $72.2 million. Following such repurchases, and as of September 30, 2013, approximately $18.4 million of our 2015 Notes remain outstanding. This repurchase was accounted for as an extinguishment of debt and we recorded a loss on extinguishment of debt of $7.9 million which comprised $5.5 million of premium paid to the holders of the 2015 Notes, $2.2 million related to the excess of the deemed issuance fair value over the issuance price (par) of the 2017 Notes (but only for those holders of the repurchased 2015 Notes who subsequently invested in our 2017 Notes) and $0.2 million related to the write-off of the initial debt issuance costs for these 2015 Notes.
	The following is a summary of the interest expense recognized on the 2017 Notes:
		Three Months				Nine Months
		Ended September 30,				Ended September 30,
		2013		2012		2013		2012
		(in thousands)
	Contractual coupon interest	$	754	$	—	$	2,079	$	—
	Accretion of debt discount		1,455		—		3,939		—
	Amortization of debt issuance costs		188		—		517		—
	Total interest expense	$	2,397	$	—	$	6,535	$	—

Embedded_Conversion_Derivative

Embedded Conversion Derivative	9 Months Ended
	Sep. 30, 2013
Embedded Conversion Derivative	'
	10. EMBEDDED CONVERSION DERIVATIVE
	FASB Accounting Standards Codification (ASC) Topic 470 (ASC 470), Accounting for Convertible Debt Instruments That May be Settled in Cash upon Conversion (Including Partial Cash Settlement) requires the issuer of convertible debt that may be settled in shares or cash upon conversion at their option, such as our 2017 Notes, to account for their liability and equity components separately by bifurcating the embedded conversion derivative (the “derivative”) from the host debt instrument. Although ASC 470 has no impact on our actual past or future cash flows, it requires us to record non-cash interest expense as the debt discount is amortized.
	As a result of the issuance of convertible notes in January 2013, our total potential outstanding common stock exceeded our authorized shares by approximately 4.3 million shares as of that date, and we were therefore required to value the derivative and recognize the fair value as a long-term liability. The fair value of this derivative at the time of issuance was $36.9 million and was recorded as the original debt discount for the purposes of accounting for the debt component of the 2017 Notes. This debt discount is being amortized as interest expense using an effective interest rate of 9.9% over the remaining 4.25 year term of the 2017 Notes.
	In accordance with authoritative guidance, the embedded conversion derivative associated with the 2017 Notes required bifurcation from the 2017 Notes and was initially accounted for as a derivative liability. On May 30, 2013, upon obtaining stockholder approval for an amendment to our certificate of incorporation increasing the authorized number of shares of our common stock, the derivative liability was marked to fair value and reclassified to stockholders’ equity. Changes in the fair value were recorded in change in value of embedded conversion derivative in the consolidated statements of operations. We determined the fair value of the derivative using a binomial lattice model. The key assumptions for determining the fair value at May 30, 2013 included the remaining time to maturity of 4.54 years, volatility of 50%, and the risk-free interest rate of 0.88%. The estimated fair value of the embedded conversion derivative was $34.5 million as of May 30, 2013 immediately prior to its reclassification to stockholders’ equity.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies	'
	11. COMMITMENTS AND CONTINGENCIES
	Details of our ongoing commitments and contingencies were described in Note 15 to our consolidated Financial Statements included in our 2012 Annual Report on Form 10-K for the fiscal year ended December 31, 2012. There have been no significant changes to these commitments and contingencies since December 31, 2012, except with respect to the entry into the settlement agreement in regards to the Shionogi matter discussed below.
	Indemnity Agreement
	On or about March 22, 2000, we entered into an Indemnity Agreement with W. Scott Harkonen M.D., who served as the Company’s chief executive officer until September 30, 2003. The Indemnity Agreement obligates us to hold harmless and indemnify Dr. Harkonen against expenses (including attorneys’ fees), witness fees, damages, judgments, fines and amounts paid in settlement and any other amounts Dr. Harkonen becomes legally obligated to pay because of any claim or claims made against him in connection with any threatened, pending or completed action, suit or proceeding, whether civil, criminal, arbitrational, administrative or investigative, to which Dr. Harkonen is a party by reason of the fact that he was a director, officer, employee or other agent of the Company. The Indemnity Agreement establishes exceptions to our indemnification obligation, including but not limited to claims “on account of Dr. Harkonen’s conduct that is established by a final judgment as knowingly fraudulent or deliberately dishonest or that constituted willful misconduct,” claims “on account of Dr. Harkonen’s conduct that is established by a final judgment as constituting a breach of Dr. Harkonen’s duty of loyalty to the Corporation or resulting in any personal profit or advantage to which Dr. Harkonen was not legally entitled,” and claims “for which payment is actually made to Dr. Harkonen under a valid and collectible insurance policy.” The Indemnity Agreement, however, obligates us to advance all expenses, including attorneys’ fees, incurred by Dr. Harkonen in connection with such proceedings, subject to an undertaking by Dr. Harkonen to repay said amounts if it shall be determined ultimately that he is not entitled to be indemnified by the Company.
	Dr. Harkonen was named as a defendant in certain civil action lawsuits instituted against us where the various complaints that were filed alleged that we fraudulently misrepresented the medical benefits of Actimmune for the treatment of IPF and promoted Actimmune for IPF. Ultimately, these complaints were dismissed. However, Dr. Harkonen also became the target of the investigation by the U.S. Department of Justice regarding the promotion and marketing of Actimmune. On March 18, 2008, a federal grand jury indicted Dr. Harkonen on two felony counts related to alleged improper promotion and marketing of Actimmune during the time Dr. Harkonen was employed by us (the “Criminal Action”). The trial in the criminal case resulted in a jury verdict on September 29, 2009, finding Dr. Harkonen guilty of one count of wire fraud related to a press release issued on August 28, 2002, and acquitting him of a second count of a misbranding charge brought under the Federal Food, Drug, and Cosmetic Act. On April 13, 2011, the Court denied Dr. Harkonen’s post-trial motions and sentenced Dr. Harkonen to three years of probation, including six months of home detention, 200 hours of community service and a fine of $20,000. The Court’s Judgment was filed on April 18, 2011. Dr. Harkonen appealed his conviction and sentence and the government cross-appealed his sentence. On March 4, 2013, the Ninth Circuit Court of Appeals issued an unpublished opinion affirming both the conviction and the sentence. Dr. Harkonen filed a petition for rehearing en banc which was denied by the Ninth Circuit Court of Appeals on May 7, 2013. On August 5, 2013, Dr. Harkonen filed a petition for a writ of certiorari seeking review by the United States Supreme Court. The government has obtained two extensions of its time to file a response to Dr. Harkonen’s petition, and its response currently is due to be filed on or before November 8, 2013. Under the terms of the Indemnity Agreement, we have an obligation to indemnify Dr. Harkonen for reasonable legal fees and costs incurred in connection with defending this action, including the petition for a writ of certiorari and any resulting review proceedings by the United States Supreme Court.
	Prior to December 2008, insurers that issued directors & officers (“D&O”) liability insurance to the Company had advanced all of Dr. Harkonen’s expenses, including attorneys’ fees, incurred in the civil action lawsuits and Criminal Action. Those insurers included National Union Fire Insurance Company of Pittsburgh, PA (“AIG”), Underwriters at Lloyd’s, London (“Lloyd’s”), and Continental Casualty Company (“CNA”). On November 19, 2008, however, the insurer that issued a $5.0 million D&O insurance policy providing coverage excess of the monetary limits of coverage provided by AIG, Lloyd’s and CNA, Arch Specialty Insurance Company (“Arch”), advised the Company that the limits of the underlying coverage were expected to be depleted by approximately December 15, 2008; that Arch “disclaimed coverage” based on misstatements and misrepresentations allegedly made by Dr. Harkonen in documents provided in the application for the Arch policy and the underlying Lloyd’s policy; and that, based on that disclaimer, Arch would not be advancing any of Dr. Harkonen’s expenses, including attorneys’ fees, incurred in the civil action lawsuits and Criminal Action.
	As a result of Arch’s disclaimer of coverage and refusal to advance expenses, including attorneys’ fees, the Company had, as of approximately December 15, 2008, become obligated to advance such expenses incurred by Dr. Harkonen in the civil action lawsuits and Criminal Action.
	On January 13, 2009, we submitted to the American Arbitration Association (“AAA”) a Demand for Arbitration, InterMune, Inc. v. Arch Specialty Insurance Co., No. 74 194 01128 08 JEMO. Dr. Harkonen also is a party to the Arbitration. The Demand for Arbitration sought an award compelling Arch to advance Dr. Harkonen’s legal fees and costs incurred in the civil action lawsuits and the Criminal Action, and to advance other former officers’ legal fees and costs incurred in relation to the Department of Justice investigation.
	The matter was heard by the arbitration panel and on May 29, 2009, the arbitration panel issued an Interim Arbitration Award granting our request for a partial award requiring Arch to advance Dr. Harkonen’s legal fees and costs incurred in the civil action lawsuits and Criminal Action. Arch subsequently advanced such fees and costs, including fees and costs previously paid by the Company. The question whether Arch ultimately will be required to cover the advanced fees and costs or, instead, may recoup those fees and costs as not covered by its policy, has not been determined. Unless and until the arbitration panel rules that such fees and costs are not covered, Arch remains obligated to advance such fees and costs. We expect that, should the United States Supreme Court deny Dr. Harkonen’s petition for writ of certiorari and leave the verdict and judgment against Dr. Harkonen intact, Arch will resume the arbitration and seek to recover all or some of the $5 million it advanced for Dr. Harkonen’s defense back from the Company and/or from Dr. Harkonen. At this time, we believe no change to the status of the Interim Arbitration Award or to the application of the D&O liability insurance in general has occurred due to the trial court judgment, and, therefore, we are unable to determine the amount of a loss or range of losses that we may incur and have not accrued for any such amounts in our financial statements associated with this matter.
	In late 2009, Arch advised us that Arch had exhausted the $5.0 million limit of liability of the Arch D&O insurance policy, and that defense cost invoices submitted to Arch collectively exceed the Arch policy’s limit. The Company therefore advised the insurer that issued a $5.0 million D&O insurance policy providing coverage for the excess of the monetary limits of coverage provided by Arch, Old Republic Insurance Company (“Old Republic”), that the limits of the underlying coverage had been depleted, and we submitted invoices for legal services rendered on behalf of Dr. Harkonen and other individuals who were targets of the U.S. Department of Justice’s investigation to Old Republic for payment. Old Republic agreed to advance Dr. Harkonen’s legal fees and costs incurred in the civil action lawsuits and Criminal Action, but declined to reimburse us for payments made on behalf of other individuals who were targets of the U.S. Department of Justice’s investigation. In mid-2010, Old Republic advised us that Dr. Harkonen’s defense fees and costs had exhausted the $5.0 million limit of the Old Republic insurance policy as of the second quarter of 2010. There is no additional insurance coverage available to cover the cost of Dr. Harkonen’s continuing defense. Defense fees and costs incurred over and above this final $5.0 million of insurance coverage therefore are, in the absence of any available insurance, to be advanced by us pursuant to the terms of the Indemnity Agreement. We expect amounts to be paid by us to continue into the future until the Criminal Action is finally adjudicated; however, we are unable to predict what our total liability could be with any degree of certainty.
	Shionogi
	In March 2012, following the EU’s grant of marketing approval for Esbriet (pirfenidone), Shionogi demanded that we agree that Shionogi is entitled to royalty payments on our sales of Esbriet (pirfenidone) in Europe, based on Shionogi’s interpretation of our May 2004 agreement with Shionogi (as amended). On July 5, 2012, Shionogi filed a complaint against us in the United States District Court for the Northern District of California. Shionogi’s complaint alleged principally that we breached that agreement with Shionogi governing the exchange and use of certain documents and information relating to the parties’ respective clinical trials of pirfenidone. The complaint alleged that we breached the agreement by utilizing certain of Shionogi’s information in our MAA and other submissions for pirfenidone with the EMA and then failing to pay royalties to Shionogi on net sales of Esbriet (pirfenidone) in the European Union. In the alternative, the complaint alleged that, if we did not use Shionogi’s information in a way that would trigger a royalty obligation under the agreement, we had an obligation to do so as an exclusive licensee. Shionogi sought, among other things, unspecified monetary damages and a declaration that we are obligated to pay royalties to Shionogi on net sales of Esbriet (pirfenidone) in the European Union. In February 2013, we reached an agreement on the material terms of a settlement with Shionogi relating to the complaint and, in May 2013, we entered into a final complete settlement agreement. The principal terms of the settlement agreement include: (i) dismissal of the litigation with prejudice; (ii) a royalty payment from us to Shionogi on net sales of Esbriet (pirfenidone) in the EU of 4.25% for sales commencing on January 1, 2013 and ending on the date of the expiration of orphan drug status in the EU (February 2021); (iii) no royalty payments on net sales of Esbriet in the EU prior to January 1, 2013; (iv) no royalty payments on sales of Esbriet in Canada; (v) no royalty payments on sales of Esbriet in the U.S. or sales in any other jurisdiction (other than the EU), unless we submit certain Shionogi clinical information in connection with an application for regulatory approval in that jurisdiction; and (vi) the Shionogi clinical information in our current NDA in the U.S. would not trigger payment of a royalty on sales of Esbriet in the U.S.

Disclosures_About_Segments_of_

Disclosures About Segments of an Enterprise and Related Information	9 Months Ended
	Sep. 30, 2013
Disclosures About Segments of an Enterprise and Related Information	'
	12. DISCLOSURES ABOUT SEGMENTS OF AN ENTERPRISE AND RELATED INFORMATION
	We have determined, in accordance with ASC 280, Segment Reporting, that our business operates in one operating segment: the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Our chief operating decision makers review financial information on a consolidated basis for purposes of making operating decisions and assessing financial performance.
	We currently market and sell Esbriet in Europe and Canada for the treatment of IPF, of which substantially all revenue is derived from Europe. Revenue from sales of Actimmune has been reclassified to discontinued operations for all periods presented and are therefore excluded from the numbers presented below.
	Our net revenue, organized by the following geographic regions: (i) United States; and (ii) Europe and other, based on the location at which each sale originates, is summarized as follows:
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013			2012
		(in thousands)
	United States	$	—		$	—		$	—		$	—
	Europe and other		19,718			7,534			44,648			17,952
	Totals	$	19,718		$	7,534		$	44,648		$	17,952
	Our net property and equipment by region are summarized as follows:
		September 30,			December 31,
		2013			2012
		(in thousands)
	United States	$	2,390		$	2,185
	Europe and other		2,228			2,147
	Totals	$	4,618		$	4,332
	We perform credit evaluations on our customers’ financial condition and limit the amount of credit extended. Concentrations of credit risk, with respect to accounts receivable, exist to the extent of amounts presented in the financial statements. We carefully monitor the creditworthiness of potential customers. As of September 30, 2013, we have not experienced any significant losses on our accounts receivable.
	Customers representing 10% or more of total product revenue during the three and nine months ended September 30, 2013 and 2012 and accounts receivable as of September 30, 2013 and December 31, 2012, were as follows:
		Revenue												Accounts Receivable
		Three Months Ended						Nine Months Ended
		September 30,						September 30,						September 30,			December 31,
		2013			2012			2013			2012			2013			2012
	Customer A		12	%		29	%		16	%		25	%		11	%		29	%

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. The financial statements include all adjustments (consisting only of normal recurring adjustments) that we believe are necessary for a fair presentation of the periods presented. The condensed consolidated balance sheet at December 31, 2012 was derived from the audited consolidated financial statements, but does not include all disclosures required by GAAP. These interim financial results are not necessarily indicative of results to be expected for the full fiscal year or any other future period and should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2012, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC).
Revenue Recognition and Revenue Reserves	'
	Revenue Recognition and Revenue Reserves
	Revenue is generated from product sales and recorded net of rebates. We only ship product upon receipt of valid orders from customers, such as pharmacies and hospitals, which are in turn a result of actual patient prescriptions. Delivery is considered to have occurred when title passes to a credit-worthy customer. We include shipping and handling costs in cost of goods sold. Pursuant to terms and conditions of sale, our customers have no rights to return our products. Such restriction on product returns is common practice in the markets in which we sell, and as a result, we have had no significant expenses related to product returns, damaged or expired goods, chargebacks, except for mandatory government rebates, or other discounts or allowances since our commercial launch in these countries. Product sales are recorded net of estimated government-mandated rebates which are fixed for negotiated periods. We review all sales transactions for potential rebates each month and believe that our reserves are adequate. Due to our limited history of selling Esbriet, we are currently accruing for these mandatory government rebates according to contractual obligation redemption rates, which represents our best estimate of the liability at this time and as we develop a more substantial history related to our rebate claims, we will continue to adjust our accrual to accurately reflect rebate claims.
Derivative Financial Instruments	'
	Derivative Financial Instruments
	On January 22, 2013, we issued $120.8 million aggregate principal amount of 2.50% convertible senior notes due 2017 (the “2017 Notes”). As a result of our issuance of the 2017 Notes, our total potential outstanding common stock exceeded our authorized shares by approximately 4.3 million shares as of that date and we were therefore required to value the embedded conversion derivative and recognize it at fair value as a long-term liability.
	On May 30, 2013, we obtained stockholder approval to an amendment to our certificate of incorporation to increase the number of our authorized shares of common stock from 100,000,000 to 175,000,000. As a result of the increase in authorized number of shares, we can now settle the 2017 Notes in cash, stock, or a combination thereof, solely at our election, the derivative associated with the embedded conversion derivative was marked to fair value at May 30, 2013 and the long-term liability was reclassified to stockholders’ equity.
	See also Note 10 for further details of our embedded conversion derivative.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is calculated based on the weighted-average number of shares of our common stock outstanding during the period, as adjusted. Diluted net loss per share is calculated based on the weighted average number of shares of our common and other dilutive securities outstanding during the period. The potential dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and shares subject to repurchase are determined under the treasury stock method. The potential dilutive shares of our common stock issuable on conversion of our convertible notes are determined using the “if-converted” method.
	For the calculation of net loss per share, securities excluded were as follows:
		As of
		September 30,
		2013			2012
		(in thousands)
	Common stock options and awards		5,797			5,252
	Shares issuable upon conversion of convertible notes		15,237			9,384
	The following table is a reconciliation of the denominator used in the calculation of basic and diluted net loss per share attributable to our common stockholders:
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013			2012
		(in thousands)
	Denominator:
	Weighted-average shares of common stock outstanding		81,942			65,779			80,604			65,497
	Less: Weighted-average shares subject to repurchase		(545	)		(596	)		(583	)		(531	)
	Weighted-average shares used in computing net loss per common share – basic and diluted		81,397			65,183			80,021			64,966
Stock-Based Compensation	'
	Stock-Based Compensation
	The following table reflects stock-based compensation expense recognized for the three and nine month periods ended September 30, 2013 and 2012:
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013			2012
		(in thousands)
	Cost of goods sold	($	4	)	$	50		$	39		$	157
	Research and development		1,044			1,070			2,708			3,510
	Selling, general and administrative		2,431			2,031			6,217			8,587
	Total stock-based compensation expense	$	3,471		$	3,151		$	8,964		$	12,254
	Under the fair value recognition provisions of Accounting Standards Codification (ASC) 718-10, Stock Compensation, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period for that portion of the award that is ultimately expected to vest. In order to estimate the value of share-based awards, we use the Black-Scholes model, which requires the use of certain subjective assumptions. The most significant assumptions are our estimates of the expected volatility, the expected term of the award and the estimated forfeiture rate
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. This ASU is an update to the reporting of reclassifications out of accumulated other comprehensive income. The guidance requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety from accumulated other comprehensive income to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. The guidance is effective for us in our first quarter of fiscal year 2014 with earlier adoption permitted, which should be applied prospectively. We adopted ASU No. 2013-02 for the period ended March 31, 2013. The adoption of this new guidance did not have an effect on our condensed consolidated balance sheets, statement of operations or cash flows.
Royalty Payments	'
Royalty Payments	'
	Royalty Payments
	We record royalty payments due on product sales within cost of goods sold. At present, the only such royalty is payable to Shionogi in relation to net sales of pirfenidone in the EU.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Calculation of Net Loss Per Share, Securities Excluded	'
	For the calculation of net loss per share, securities excluded were as follows:
		As of
		September 30,
		2013			2012
		(in thousands)
	Common stock options and awards		5,797			5,252
	Shares issuable upon conversion of convertible notes		15,237			9,384
Reconciliation of Denominator Used in Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	'
	The following table is a reconciliation of the denominator used in the calculation of basic and diluted net loss per share attributable to our common stockholders:
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013			2012
		(in thousands)
	Denominator:
	Weighted-average shares of common stock outstanding		81,942			65,779			80,604			65,497
	Less: Weighted-average shares subject to repurchase		(545	)		(596	)		(583	)		(531	)
	Weighted-average shares used in computing net loss per common share – basic and diluted		81,397			65,183			80,021			64,966
Stock-Based Compensation Expense Recognized	'
	The following table reflects stock-based compensation expense recognized for the three and nine month periods ended September 30, 2013 and 2012:
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013			2012
		(in thousands)
	Cost of goods sold	$	(4	)	$	50		$	39		$	157
	Research and development		1,044			1,070			2,708			3,510
	Selling, general and administrative		2,431			2,031			6,217			8,587
	Total stock-based compensation expense	$	3,471		$	3,151		$	8,964		$	12,254

Discontinued_Operations_Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2013
Operating Results and Gain on Sale of Discontinued Operations	'
	Summary operating results for the discontinued operations are as follows:
		Three Months					Nine Months
		Ended September 30,					Ended September 30,
		2013		2012			2013		2012
		(in thousands)
	Actimmune revenue, net	$	500	$	—		$	1,500	$	6,627
	Costs and expenses:
	Cost of goods sold		—		(198	)		—		4,276
	General and administrative		15		66			80		226
	Total costs and expenses		15		(132	)		80		4,502
	Income from discontinued operations		485		132			1,420		2,125
	Gain on sale of discontinued operations		—		—			—		51,335
	Income and gains related to discontinued operations, before tax		485		132			1,420		53,460
	Income tax expense		165		48			483		19,321
	Income from discontinued operations, net of taxes	$	320	$	84		$	937	$	34,139

Fair_Value_Tables

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2013
Financial Assets Measured at Fair Value on Recurring Basis	'
	The following table represents the fair value hierarchy for our financial assets which require fair value measurement on a recurring basis as of September 30, 2013 and December 31, 2012:
		As of September 30, 2013
		(in thousands)
	Assets	Level 1		Level 2		Level 3			Total
	Money market funds	$	24,532	$	—	$	—		$	24,532
	Obligations of government-sponsored enterprises		—		181,489		—			181,489
	Corporate debt securities		—		27,975		—			27,975
	Commercial paper		—		10,495		—			10,495
	Total	$	24,532	$	219,959	$	—		$	244,491
		As of December 31, 2012
		(in thousands)
	Assets	Level 1		Level 2		Level 3			Total
	Money market funds	$	7,777	$	—	$	—		$	7,777
	Obligations of government-sponsored enterprises		—		144,806		—			144,806
	Corporate debt securities		—		31,438		—			31,438
	Commercial paper		—		32,891		—			32,891
	Total	$	7,777	$	209,135	$	—		$	216,912
Summary of Carrying and Fair Value of Convertible Notes	'
	The following table summarizes the carrying and fair value of our Level 2 convertible senior notes as of September 30, 2013 and December 31, 2012:
		As of September 30, 2013				As of December 31, 2012
		(in thousands)
		Carrying value		Fair value		Carrying value			Fair value
	Convertible senior notes due 2015	$	18,360	$	21,514	$	85,000		$	85,286
	Convertible senior notes due 2017		90,001		170,102		—			—
	Convertible senior notes due 2018		155,250		140,389		155,250			121,326
	Total	$	263,611	$	332,005	$	240,250		$	206,612
Fair Values of Financial Instruments	'
	The following table sets forth the changes in the estimated fair value for our Level 3 classified embedded conversion derivative:
		Three Months				Nine Months
		Ended September 30,				Ended September 30,
		2013		2012		2013			2012
		(in thousands)
	Fair value measurement at beginning of period	$	—	$	—	$	—		$	—
	Embedded conversion derivative recorded in connection with 2017 Notes		—		—		36,887			—
	Change in fair value measurement included in operating expenses		—		—		(2,422	)		—
	Derivative liability reclassified to stockholders’ equity		—				(34,465	)
	Fair value measurement at end of period	$	—	$	—	$	—		$	—

Cash_Equivalents_and_Available1

Cash Equivalents and Available-For-Sale Securities (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Available-For-Sale Debt and Equity Securities Included in Cash and Cash Equivalents or Available-for-Sale Securities	'
	The following table is a summary of available-for-sale debt and equity securities included in cash and cash equivalents or available-for-sale securities:
	September 30, 2013	Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(in thousands)
	Money market funds	$	24,532	$	—	$	—	$	24,532
	Obligations of government-sponsored enterprises		181,375		114		—		181,489
	Corporate debt securities		27,957		18		—		27,975
	Commercial paper		10,495		—		—		10,495
	Total	$	244,359	$	132	$	—	$	244,491
		Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(in thousands)
	Reported as:
	Cash equivalents	$	24,532	$	—	$	—	$	24,532
	Available-for-sale securities		219,827		132		—		219,959
	Total	$	244,359	$	132	$	—	$	244,491
	December 31, 2012	Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(in thousands)
	Money market funds	$	7,777	$	—	$	—	$	7,777
	Obligations of government-sponsored enterprises		144,747		59		—		144,806
	Corporate debt securities		31,382		56		—		31,438
	Commercial paper		32,890		1		—		32,891
	Total	$	216,796	$	116	$	—	$	216,912
		Amortized		Gross		Gross		Fair Value
		Cost		Unrealized		Unrealized
				Gains		Losses
		(in thousands)
	Reported as:
	Cash equivalents	$	26,674	$	—	$	—	$	26,674
	Available-for-sale securities		190,122		116		—		190,238
	Total	$	216,796	$	116	$	—	$	216,912
Summary of Amortized Cost and Estimated Fair Value of Available-For-Sale Securities	'
	The following is a summary of the amortized cost and estimated fair value of available-for-sale securities by contractual maturity:
		September 30, 2013
		Amortized		Fair Value
		Cost
		(in thousands)
	Mature in less than one year	$	189,027	$	189,112
	Mature in one to three years		55,332		55,379
	Total	$	244,359	$	244,491

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Inventory	'
	Inventories consist of the following:
		September 30,		December 31,
		2013		2012
		(in thousands)
	Raw materials	$	7,878	$	7,310
	Work in process		1,461		1,097
	Finished goods		1,084		1,613
	Total	$	10,423	$	10,020

Comprehensive_Loss_Tables

Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2013
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	The balance of accumulated other comprehensive income (loss), net of taxes, was as follows:
		Foreign		Unrealized gains		Accumulated
		Currency		(losses) on		other
				securities		comprehensive
						income
		(in thousands)
	Balance at December 31, 2012	$	385	$	116	$	501
	Comprehensive loss		181		16		197
	Balance at September 30, 2013	$	566	$	132	$	698

Convertible_Notes_Tables

Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2013
Convertible Senior Notes Due 2017	'
Summary of Interest Expense Recognized	'
	The following is a summary of the interest expense recognized on the 2017 Notes:
		Three Months				Nine Months
		Ended September 30,				Ended September 30,
		2013		2012		2013		2012
		(in thousands)
	Contractual coupon interest	$	754	$	—	$	2,079	$	—
	Accretion of debt discount		1,455		—		3,939		—
	Amortization of debt issuance costs		188		—		517		—
	Total interest expense	$	2,397	$	—	$	6,535	$	—
5.00% Convertible Senior Notes Due 2015 and 2.50% Convertible Senior Notes Due 2018	'
Summary of Interest Expense Recognized	'
	The following is a summary of the interest expense recognized on the 2015 and 2018 Notes:
		Three Months				Nine Months
		Ended September 30,				Ended September 30,
		2013		2012		2013		2012
		(in thousands)
	Convertible senior notes due 2015	$	235	$	1,087	$	907	$	3,260
	Convertible senior notes due 2018		1,150		1,150		3,450		3,450
	Total interest expense	$	1,385	$	2,237	$	4,357	$	6,710

Disclosures_About_Segments_of_1

Disclosures About Segments of an Enterprise and Related Information (Tables)	9 Months Ended
	Sep. 30, 2013
Net Revenue by Region	'
	Our net revenue, organized by the following geographic regions: (i) United States; and (ii) Europe and other, based on the location at which each sale originates, is summarized as follows:
		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013			2012
		(in thousands)
	United States	$	—		$	—		$	—		$	—
	Europe and other		19,718			7,534			44,648			17,952
	Totals	$	19,718		$	7,534		$	44,648		$	17,952
Net Property and Equipment by Region	'
	Our net property and equipment by region are summarized as follows:
		September 30,			December 31,
		2013			2012
		(in thousands)
	United States	$	2,390		$	2,185
	Europe and other		2,228			2,147
	Totals	$	4,618		$	4,332
Revenue from Customers Representing Ten Percentage or More of Total Product Revenue and Accounts Receivable	'
	Customers representing 10% or more of total product revenue during the three and nine months ended September 30, 2013 and 2012 and accounts receivable as of September 30, 2013 and December 31, 2012, were as follows:
		Revenue												Accounts Receivable
		Three Months Ended						Nine Months Ended
		September 30,						September 30,						September 30,			December 31,
		2013			2012			2013			2012			2013			2012
	Customer A		12	%		29	%		16	%		25	%		11	%		29	%

Organization_Additional_Inform

Organization - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2012	Sep. 30, 2013
		Patient
Organization and Nature of Operations [Line Items]	'	'
Number of patients	'	555
Proceeds from divestiture of Actimmune	$55	'
Royalty payments period	'2 years	'
European Union | Marketing Authorization	'	'
Organization and Nature of Operations [Line Items]	'	'
Number of member countries of the European Union ("EU") in which marketing authorization is granted	'	28

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	Sep. 30, 2013	30-May-13	Dec. 31, 2012	Jan. 31, 2013	Jan. 22, 2013
In Millions, except Share data, unless otherwise specified				2.50% Convertible Senior Notes Due 2017	Senior Notes Issued
					2.50% Convertible Senior Notes Due 2017
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'
Total potential outstanding common stock in excess of authorized shares	'	'	'	4,300,000	'
Debt instrument, issued	'	'	'	'	$120.80
Common stock, Shares authorized	175,000,000	175,000,000	100,000,000	'	'

Shares_Excluded_Detail

Shares Excluded (Detail)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Common stock options and awards	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities excluded from calculation of net loss per share	5,797	5,252
Shares issuable upon conversion of convertible notes	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities excluded from calculation of net loss per share	15,237	9,384

Reconciliation_of_Numerator_an

Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Schedule Of Calculation Of Numerator And Denominator In Earnings Per Share [Line Items]	'	'	'	'
Weighted-average shares of common stock outstanding	81,942	65,779	80,604	65,497
Less: Weighted-average shares subject to repurchase	-545	-596	-583	-531
Weighted-average shares used in computing net loss per common share - basic and diluted	81,397	65,183	80,021	64,966

StockBased_Compensation_Expens

Stock-Based Compensation Expense Recognized (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	$3,471	$3,151	$8,964	$12,254
Cost of goods sold	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	-4	50	39	157
Research and development	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	1,044	1,070	2,708	3,510
Selling, General and Administrative Expenses	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total stock-based compensation expense	$2,431	$2,031	$6,217	$8,587

Discontinued_Operations_Additi

Discontinued Operations - Additional Information (Detail) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Proceeds from divestiture of Actimmune	$55
Conditional royalty payment period	'2 years

Summary_Operating_Results_for_

Summary Operating Results for Discontinued Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Actimmune revenue, net	$500	'	$1,500	$6,627
Costs and expenses:	'	'	'	'
Cost of goods sold	'	-198	'	4,276
General and administrative	15	66	80	226
Total costs and expenses	15	-132	80	4,502
Income from discontinued operations	485	132	1,420	2,125
Gain on sale of discontinued operations	'	'	'	51,335
Income and gains related to discontinued operations, before tax	485	132	1,420	53,460
Income tax expense	165	48	483	19,321
Income from discontinued operations, net of taxes	$320	$84	$937	$34,139

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
	USD ($)	USD ($)	USD ($)	USD ($)	EUR (€)	EUR (€)
Derivative [Line Items]	'	'	'	'	'	'
Derivative financial instruments not designated as hedges, net loss	$0.50	$0.20	$0.40	$0	'	'
Notional value of outstanding currency hedges	'	'	'	'	9.5	6
Fair value of outstanding derivatives	'	'	'	'	€ 0	€ 0

Financial_Assets_Measured_at_F

Financial Assets Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	$244,491	$216,912
Money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	24,532	7,777
Obligations of government-sponsored enterprises	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	181,489	144,806
Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	27,975	31,438
Commercial paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	10,495	32,891
Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	24,532	7,777
Level 1 | Money market funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	24,532	7,777
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	219,959	209,135
Level 2 | Obligations of government-sponsored enterprises	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	181,489	144,806
Level 2 | Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	27,975	31,438
Level 2 | Commercial paper	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	$10,495	$32,891

Summary_of_Carrying_and_Fair_V

Summary of Carrying and Fair Value of Convertible Notes (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Carrying Value Disclosure	'	'
Carrying Amounts and Fair Values of Financial Instruments [Line Items]	'	'
Convertible senior notes, carrying value	$263,611	$240,250
Carrying Value Disclosure | Convertible Senior Notes Due 2015	'	'
Carrying Amounts and Fair Values of Financial Instruments [Line Items]	'	'
Convertible senior notes, carrying value	18,360	85,000
Carrying Value Disclosure | Convertible Senior Notes Due 2017	'	'
Carrying Amounts and Fair Values of Financial Instruments [Line Items]	'	'
Convertible senior notes, carrying value	90,001	'
Carrying Value Disclosure | Convertible Senior Notes Due 2018	'	'
Carrying Amounts and Fair Values of Financial Instruments [Line Items]	'	'
Convertible senior notes, carrying value	155,250	155,250
Fair Value	'	'
Carrying Amounts and Fair Values of Financial Instruments [Line Items]	'	'
Convertible senior notes, fair value	332,005	206,612
Fair Value | Convertible Senior Notes Due 2015	'	'
Carrying Amounts and Fair Values of Financial Instruments [Line Items]	'	'
Convertible senior notes, fair value	21,514	85,286
Fair Value | Convertible Senior Notes Due 2017	'	'
Carrying Amounts and Fair Values of Financial Instruments [Line Items]	'	'
Convertible senior notes, fair value	170,102	'
Fair Value | Convertible Senior Notes Due 2018	'	'
Carrying Amounts and Fair Values of Financial Instruments [Line Items]	'	'
Convertible senior notes, fair value	$140,389	$121,326

Estimated_Fair_Value_for_Level

Estimated Fair Value for Level 3 Classified Embedded Conversion Derivative (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	30-May-13	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011
Carrying Amounts and Fair Values of Financial Instruments [Line Items]	'	'	'	'	'	'
Fair value measurement at beginning of period	'	'	$34,500,000	'	'	'
Embedded conversion derivative recorded in connection with 2017 Notes	36,887,000	'	'	'	'	'
Change in fair value measurement included in operating expenses	-2,422,000	'	'	'	'	'
Derivative liability reclassified to stockholders' equity	-34,465,000	'	'	'	'	'
Fair value measurement at end of period	'	'	$34,500,000	'	'	'

Summary_of_AvailableForSale_De

Summary of Available-For-Sale Debt and Equity Securities Included in Cash and Cash Equivalents or Available-for-Sale Securities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$244,359	$216,796
Gross Unrealized Gains	132	116
Gross Unrealized Losses	'	'
Available-for-sale securities, Fair Value, Total	244,491	216,912
Cash equivalents	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	24,532	26,674
Gross Unrealized Losses	'	'
Available-for-sale securities, Fair Value, Total	24,532	26,674
Available-for-sale securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	219,827	190,122
Gross Unrealized Gains	132	116
Gross Unrealized Losses	'	'
Available-for-sale securities, Fair Value, Total	219,959	190,238
Money market funds	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	24,532	7,777
Gross Unrealized Losses	'	'
Available-for-sale securities, Fair Value, Total	24,532	7,777
Obligations of government-sponsored enterprises	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	181,375	144,747
Gross Unrealized Gains	114	59
Gross Unrealized Losses	'	'
Available-for-sale securities, Fair Value, Total	181,489	144,806
Corporate debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	27,957	31,382
Gross Unrealized Gains	18	56
Gross Unrealized Losses	'	'
Available-for-sale securities, Fair Value, Total	27,975	31,438
Commercial paper	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	10,495	32,890
Gross Unrealized Gains	'	1
Gross Unrealized Losses	'	'
Available-for-sale securities, Fair Value, Total	$10,495	$32,891

Cash_Equivalents_and_Available2

Cash Equivalents and Available-For-Sale Securities - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Realized gains on redemptions and sales of auction rate securities	$0	$0	$2,000	$0

Summary_of_Amortized_Cost_and_

Summary of Amortized Cost and Estimated Fair Value of Available for Sale Securities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Mature in less than one year, Amortized Cost	$189,027	'
Available-for-sale securities, Mature in one to three years, Amortized Cost	55,332	'
Available-for-sale securities, Amortized Cost, Total	244,359	'
Available-for-sale securities, Mature in less than one year, Fair Value	189,112	'
Available-for-sale securities, Mature in one to three years, Fair Value	55,379	'
Available-for-sale securities, Fair Value, Total	$244,491	$216,912

Schedule_of_Inventory_Detail

Schedule of Inventory (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Raw materials	$7,878	$7,310
Work in process	1,461	1,097
Finished goods	1,084	1,613
Total	$10,423	$10,020

Schedule_of_Accumulated_Other_

Schedule of Accumulated Other Comprehensive Income (Loss) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning Balance	'	'	$385	'
Comprehensive loss	845	-755	181	-536
Ending Balance	566	'	566	'
Beginning Balance	'	'	116	'
Comprehensive loss	'	'	16	'
Ending Balance	132	'	132	'
Beginning Balance	'	'	501	'
Comprehensive loss	'	'	197	'
Ending Balance	$698	'	$698	'

Comprehensive_Loss_Additional_

Comprehensive Loss - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other income (expense)	($851,000)	$975,000	($945,000)	($149,000)
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Net Unrealized Investment Gain (Loss)	'	'	'	'
Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other income (expense)	$0	$0	$2,000	$0

Convertible_Notes_Additional_I

Convertible Notes - Additional Information (Detail) (USD $)

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Jun. 30, 2008

Sep. 30, 2013

Jan. 31, 2013

Sep. 30, 2011

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jan. 31, 2013

Jan. 31, 2013

Jan. 31, 2013

Jan. 22, 2013

Convertible Senior Notes Due 2015

Convertible Senior Notes Due 2015

Convertible Senior Notes Due 2015

Convertible Senior Notes Due 2018

Convertible Senior Notes Due 2018

Convertible Senior Notes Due 2017

Minimum

Maximum

Public Offerings

Public Offerings

Senior Notes Issued

Senior Notes Issued

Y

Repurchase

Y

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Common Stock Offering

Convertible Senior Notes Due 2017

Convertible Senior Notes Due 2017

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument amount outstanding

$263,611,000

$240,250,000

$85,000,000

$18,400,000

$18,400,000

$155,300,000

$155,300,000

'

'

'

'

'

'

'

Convertible senior notes, interest rate percentage

'

'

5.00%

'

'

2.50%

'

'

'

'

'

'

'

2.50%

Debt instrument maturity date

'

'

1-Mar-15

'

'

15-Sep-18

'

15-Dec-17

'

'

'

'

'

'

Conversion rate

'

'

'1,000 aggregate principal amount of the 2015 Notes is 52.9661 shares of common stock

'

'

'1,000 aggregate principal amount of the 2018 Notes is 31.4465 shares of common stock

'

'77.7001 shares per $1,000 principal amount

'

'

'

'

'

'

Conversion price

'

'

$18.88

'

'

$31.80

'

$12.87

'

'

'

'

'

'

Offering expenses and underwriting discounts

'

'

600,000

'

'

5,000,000

'

'

'

'

'

'

'

'

Period from inception in which interest expense is amortized, years

'

'

7

'

'

7

'

'

'

'

'

'

'

'

Common stock issued, shares

'

'

'

'

'

'

'

'

'

'

15,525,000

'

'

'

Debt instrument, issued

'

'

'

'

'

'

'

'

'

'

'

'

'

120,800,000

Convertible senior notes, maturity date

'

'

'

'

'2015

'

'

'

'

'

'

'

'Due December 15, 2017

'

Aggregate net proceeds from common stock offerings

'

'

'

'

'

'

'

'

'

'

'

145,700,000

'

'

Aggregate net proceeds from convertible note offering

'

'

'

'

'

'

'

'

'

'

'

'

116,800,000

'

Convertible note conversion condition

'

'

'

'

'

'

'

'a)B during any fiscal quarter beginning after JuneB 30, 2013, if the last reported sale price of our common stock for at least 20 trading days during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; b)B during the five consecutive business day period after any five consecutive trading day period in which the trading price of the 2017 Notes falls below 98% of the product of (i)B the last reported sale price of the Companybs common stock and (ii)B the applicable conversion rate on each such trading date; c)B if we call the 2017 Notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; and d)B upon the occurrence of specified corporate events, as defined in the 2017 Notes.

'

'

'

'

'

'

Number of consecutive trading days used in conversion analysis

'

'

'

'

'

'

'

'30 days

'20 days

'

'

'

'

'

Market price of common stock exceeding percent of the conversion price

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

Number of consecutive business days for the market price of notes to fall below the 98% threshold

'

'

'

'

'

'

'

'5 days

'

'

'

'

'

'

Number of consecutive trading days for the market price of notes to fall below the 98% threshold

'

'

'

'

'

'

'

'5 days

'

'

'

'

'

'

Market price of notes declining to percent of the value of the common stock

'

'

'

'

'

'

'

'

'

98.00%

'

'

'

'

Debt instrument repurchased amount

'

'

'

'

66,600,000

'

'

'

'

'

'

'

'

'

Repurchase of convertible senior notes

72,183,000

'

'

72,200,000

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of debt

-7,900,000

'

'

-7,900,000

'

'

'

'

'

'

'

'

'

'

Premium paid to the holders

'

'

'

5,500,000

'

'

'

'

'

'

'

'

'

'

Excess of deemed issuance fair value over issuance price

'

'

'

2,200,000

'

'

'

'

'

'

'

'

'

'

Write-off of the initial debt issuance costs

'

'

'

$200,000

'

'

'

'

'

'

'

'

'

'

Summary_of_Interest_Expense_Re

Summary of Interest Expense Recognized on 2015 and 2018 Notes (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Convertible Senior Notes Due 2015	'	'	'	'
Interest Expense [Line Items]	'	'	'	'
Total interest expense	$235	$1,087	$907	$3,260
Convertible Senior Notes Due 2018	'	'	'	'
Interest Expense [Line Items]	'	'	'	'
Total interest expense	1,150	1,150	3,450	3,450
5.00% Convertible Senior Notes Due 2015 and 2.50% Convertible Senior Notes Due 2018	'	'	'	'
Interest Expense [Line Items]	'	'	'	'
Total interest expense	$1,385	$2,237	$4,357	$6,710

Summary_of_Interest_Expense_Re1

Summary of Interest Expense Recognized (Detail) (Convertible Senior Notes Due 2017, USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Convertible Senior Notes Due 2017	'	'
Interest Expense [Line Items]	'	'
Contractual coupon interest	$754	$2,079
Accretion of debt discount	1,455	3,939
Amortization of debt issuance costs	188	517
Total interest expense	$2,397	$6,535

Embedded_Conversion_Derivative1

Embedded Conversion Derivative - Additional Information (Detail) (USD $)	9 Months Ended							1 Months Ended
Share data in Millions, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	30-May-13	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Dec. 31, 2011	Jan. 31, 2013
								2.50% Convertible Senior Notes Due 2017
Derivative [Line Items]	'	'	'	'	'	'	'	'
Total potential outstanding common stock in excess of authorized shares	'	'	'	'	'	'	'	4.3
Embedded conversion derivative recorded in connection with 2017 Notes	$36,887,000	'	'	'	'	'	'	$36,900,000
Effective interest rate	'	'	'	'	'	'	'	9.90%
Debt discount amortization period	'	'	'	'	'	'	'	'4 years 3 months
Fair value assumptions, maturity period	'4 years 6 months 15 days	'	'	'	'	'	'	'
Fair value assumptions, volatility rates	50.00%	'	'	'	'	'	'	'
Fair value assumptions, risk free interest rate	0.88%	'	'	'	'	'	'	'
Fair value assumptions, embedded conversion derivative	'	'	$34,500,000	'	'	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	Apr. 30, 2011	Mar. 18, 2008	Feb. 28, 2013	Dec. 31, 2009
			Royalty Agreements	Directors And Officers Insurance Policy
Loss Contingencies [Line Items]	'	'	'	'
Number of felony counts indicted on Dr. Harkonen	'	2	'	'
Carrying amount of insurance policy	$20,000	'	'	$5,000,000
Percentage of royalty payment to Shionogi on EU sales	'	'	4.25%	'

Disclosures_About_Segments_of_2

Disclosures About Segments of an Enterprise and Related Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
	Segment
Concentration Risk [Line Items]	'
Number of operating segment	1

Net_Revenue_by_Region_Detail

Net Revenue by Region (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	$19,718	$7,534	$44,648	$17,952
United States	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	'	'	'	'
Europe And Other	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	$19,718	$7,534	$44,648	$17,952

Net_Property_and_Equipment_by_

Net Property and Equipment by Region (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'	'
Net long-lived assets	$4,618	$4,332
United States	'	'
Segment Reporting Information [Line Items]	'	'
Net long-lived assets	2,390	2,185
Europe And Other	'	'
Segment Reporting Information [Line Items]	'	'
Net long-lived assets	$2,228	$2,147

Revenue_from_Customers_Represe

Revenue from Customers Representing Ten Percentage or More of Total Product Revenue and Accounts Receivable (Detail) (Customer A)	9 Months Ended	12 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
	Credit Concentration Risk	Credit Concentration Risk	Customer Concentration Risk	Customer Concentration Risk	Customer Concentration Risk	Customer Concentration Risk
	Accounts Receivable	Accounts Receivable	Sales	Sales	Sales	Sales
Revenue, Major Customer [Line Items]	'	'	'	'	'	'
Concentration of risk percentage	11.00%	29.00%	12.00%	29.00%	16.00%	25.00%